

Forum Review Article

Going Ape as an Approach to Cancer Therapeutics

Aditi Bapat,¹ Melissa L. Fishel,² and Mark R. Kelley^{1,2,3}

Abstract

The DNA base excision repair (BER) pathway repairs alkylation and oxidative DNA damage caused by endogenous and exogenous agents, including chemotherapeutic agents. Upon removal of the damaged base AP endonuclease 1 (Ape1), a critical component of the pathway cleaves the abasic site to facilitate repair. Ape1 is a multifunctional protein which plays a role not only in DNA repair but it also functions as a reduction–oxidation factor, known as Ref-1 in the literature, to increase the DNA binding ability of several transcription factors involved in different growth signaling pathways. Elevated levels of Ape1 have been linked to resistance to chemotherapy, poor prognosis, and poor survival. Reducing the amount of Ape1 protein in cancer cells and tumors using RNA interference and anti-sense oligonucleotide technology sensitizes mammalian tumor cells to a variety of laboratory and chemotherapeutic agents. Therefore, selective inhibition of Ape1's DNA repair activity is a promising avenue to develop novel cancer therapeutics. *Antioxid. Redox Signal.* 11, 651–667.

Introduction

Importance of DNA repair pathways and cancer

DNA REPAIR PATHWAYS PROTECT THE GENOME from damage caused by endogenous and exogenous DNA damaging agents, including chemotherapeutic agents and radiation damage (24, 44); the persistence of unrepaired DNA damage results in cell cycle arrest, apoptosis, and accumulation of mutations (47, 87). To protect cellular DNA, several DNA repair pathways such as the Base Excision Repair (BER), Nucleotide Excision Repair (NER), Mismatch Repair (MMR), Homologous Recombination (HR), and Nonhomologous End Joining (NHEJ) exist in the cell to ensure temporal and efficient repair of a variety of damage (24, 44). In addition, the importance of multiple DNA repair pathways is highlighted by several syndromes with a predisposition to cancer, which harbor germline mutations in DNA repair genes. Currently, chemotherapy and radiation therapy are the mainstream treatment options available to treat cancers. Most of the chemotherapeutic drugs act by damaging DNA which leads to an accumulation of damage resulting in impaired cell signaling and ultimately causing cell death (56). Normal cells are proficient in all forms of DNA repair; how-

ever, deficiency of a particular DNA repair pathway in cancer cells can lead to elevated levels of other DNA repair pathway proteins, leading to efficient repair of DNA damage and reducing the efficacy of cancer therapy. Cancer cells deficient in the proteins of the HR pathway, for instance, may be unable to repair damage efficiently through this pathway and may look to compensate for this deficiency by completing repair through alternative pathways such as the NHEJ or BER pathway (16, 40, 76, 82). The ability of cancer cells to identify and repair such DNA damage undermines the efficacy of these agents, and acquired or intrinsic cellular resistance to these clinical DNA-damaging agents is governed by the enhanced or elevated levels of DNA repair proteins (12, 31, 59, 90). Although it may sound paradoxical to inhibit DNA repair pathway proteins since cancer promotion and deregulated cellular growth is aided by deficient DNA repair pathways, a fine balance exists between induction of DNA damage and its efficient repair that is often responsible for resistance to chemotherapy (12, 92). Thus, inhibiting specific proteins from DNA repair pathways in cancer cells would provide us with a selective way to sensitize cancer cells to chemotherapeutic agents (90, 92). Additionally, combining DNA repair inhibition with other current chemotherapy regimens (16) and thus developing targeted thera-

Departments of ¹Biochemistry and Molecular Biology, ²Pediatrics (Section of Hematology/Oncology), Herman B Wells Center for Pediatric Research, and ³Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana.




FIG. 1. Overview of base excision repair (BER) pathway. The BER pathway is responsible for repairing damage induced by endogenous and exogenous agents, including chemotherapeutic agents. Repair is initiated by a damage-specific DNA glycosylase, that removes the damaged base to generate apurinic/apyrimidinic (AP) sites. AP sites can also be generated as a result of spontaneous base hydrolysis. Monofunctional DNA glycosylases remove the damaged base to generate an AP site, whereas bifunctional glycosylases in addition to excising the damaged base also nick the phosphodiester backbone, 3' to the AP site. AP endonuclease 1 (Ape1), a critical component of the BER pathway, then processes the AP sites by hydrolyzing the backbone 5' to the AP site to generate 3'OH and 5'dRP groups. The 5'dRP group is removed by the dRPase function of DNA polymerase β and it also fills in the correct base. Repair is completed by DNA ligase III/XRCC1 by sealing the nick. In the major short-patch (SP) BER path-

way, regular AP sites are repaired by the removal of the single damaged base. Modified or oxidized AP sites are repaired by the long-patch (LP) BER pathway where a flap of 3–8 nucleotides is displaced and excised by Fen1. DNA polymerase β , δ , or ϵ then inserts the correct nucleotides and repair is completed by sealing of the nick by DNA ligase I.

pies are generating robust interest. Here we describe the DNA Base Excision Repair (BER) pathway with a focus on Ape1 as a targeted approach to cancer therapeutics.

DNA base excision repair (BER) pathway

The DNA base excision repair (BER) pathway repairs alkylation and oxidative damage caused by endogenous and exogenous agents, including radiation and chemotherapy-induced damage (24, 44). The BER pathway recognizes and repairs single base lesions including *N*-alkylated purines (*N*3-methyladenine, *N*7-methylguanine, and *N*3-methylguanine), 8-oxo-7,8-dihydroguanine (8-OxoG), thymine glycols, 5-OH and 6-OH dihydrothymine, uracil glycol, 5-hydroxycytosine, and urea residues, in addition to a number of additional adducts (4, 24, 37). Repair of the damaged base is initiated by a DNA glycosylase (Fig. 1) which specifically recognizes and excises the damaged base. Different DNA glycosylases recognize specific and different types of base damage. Glycosylases are of two types—monofunctional and bifunctional glycosylases. Monofunctional glycosylases [e.g., *N*-methyl purine DNA glycosylase (MPG)] excise the damaged base to generate an apurinic/apyrimidinic (AP) or abasic site. In contrast, bifunctional glycosylases, in addition to exhibiting glycosylase activity, also have an AP lyase function (20, 27). Bifunctional glycosylases such as 8-oxoguanine DNA glycosylase (OGG1), Nei endonuclease VII like, NEIL1, NEIL2, and NTH not only excise the damaged base but also nick the phosphodiester backbone 3' to the AP site (24, 37). Removal of the damaged base by a DNA glycosylase creates

an AP site, and AP sites are also generated by spontaneous base loss in the genome (29, 87).

The second critical component of the pathway is the multifunctional protein apurinic/apyrimidinic endonuclease (Ape1). Following hydrolysis by a DNA glycosylase, Ape1 processes the AP site by making an incision in the phosphodiester backbone immediately 5' to the AP site. This incision creates 3'OH and 5' deoxyribose phosphate (5'dRP) termini. At this stage, repair can proceed via one of two pathways (Fig. 1). The short-patch BER (SP-BER) pathway repairs regular AP sites. In the short-patch pathway, DNA polymerase β (Pol β) removes the 5'dRP moiety via its dRPase activity and uses the 3'OH terminus to insert the correct base. Subsequently, DNA ligase III/XRCC1 (X-ray cross-species complementing 1) seals the nick and repair is completed. The long-patch BER (LP-BER) pathway preferentially repairs modified (oxidized, reduced) AP sites. In this minor BER pathway, a flap of three to eight nucleotides surrounding the AP site is displaced. The correct nucleotides are inserted by DNA polymerase β , δ , or ϵ , along with proliferating cell nuclear antigen (PCNA) and replication factor-C (RF-C). Following resynthesis, flap endonuclease 1 (FEN1) removes the displaced strand and then the nick is sealed by DNA Ligase I or DNA Ligase III/XRCC1 (37). Oxidative DNA lesions can also be excised by the recently identified Nei glycosylases NEIL1 and NEIL2 that show homology to the *E. coli* endonuclease VIII (5, 53–55, 69, 122). The AP sites generated are processed by Ape1 and subsequent repair is completed. While there are several different DNA glycosylases to excise the damaged base and generate AP sites, there is only one

Ape1 protein, which can process the AP sites generated and facilitate repair, thus emphasizing its significance in the BER pathway.

The Ape1 protein, an essential component of the BER pathway

Based on the method of incision, AP endonucleases can be classified into two classes. The Class I AP endonucleases are also known as AP lyases (or β -lyases) as they process the AP sites by the β -elimination reaction and cleave the phosphodiester backbone 3' to the AP site, generating a 5' phosphate and a 3' α,β -unsaturated aldehyde end. This AP lyase activity is usually associated with complex DNA glycosylases which are responsible for repairing oxidatively damaged DNA (27). The *Escherichia coli* endonuclease III and endonuclease VIII (52) and the human homologue NTH1 (57, 58, 64) belong to this class of endonucleases. Class II AP endonucleases are the major class of endonucleases and are also known as hydrolytic endonucleases, as they hydrolyze the phosphodiester backbone 5' to the AP site, creating normal 3'OH and 5' deoxyribose phosphate termini. Based on homology, Class II AP endonucleases can be further classified into two families, the exonuclease III (xth) and the endonuclease IV (nfo) family. The exonuclease III family consists of human Ape1 in addition to enzymes from various phyla, and these enzymes possess a strong AP endonuclease activity (29, 37, 110, 119, 133). In addition to the endonuclease activity, Ape1 also possesses a 3'-repair diesterase activity. Although this 3'-repair diesterase activity is much weaker (almost 200-fold weaker) (20) than the AP endonuclease activity, it is important in the removal of 3' blocking lesions such as phosphoglycolate moieties in order to complete repair (20, 37, 42, 104). In the BER pathway, Ape1 is responsible for processing AP sites generated as a result of the action of both types of DNA glycosylases (29, 32, 117). This processing of AP sites by Ape1 then facilitates complete repair of the damaged base. The endonuclease IV family of enzymes is the second major family of Class II AP endonucleases which include the *E. coli* endonuclease IV and Apn1 from *Saccharomyces cerevisiae* (yeast) which is responsible for 90% of AP endonuclease activity in *S. cerevisiae* (37, 73, 108, 128). Apn1 can repair both alkylation and oxidative damage, including oxidized abasic sites and unlike Ape1, Apn1 has a higher 3' repair-diesterase activity (43). Although the enzymes from both families share the AP endonuclease function, they do not share sequence or structural similarity (29, 99).

Functions of Ape1

The AP endonuclease activity of Ape1

Ape1 is responsible for 95% of the endonuclease activity in the cell and is a critical part of both the short-patch and the long-patch BER pathway (29, 32, 117). Recognition of the damaged base by a monofunctional DNA glycosylase and its subsequent removal generates an AP site. This AP site is recognized by Ape1 that hydrolyzes the phosphodiester backbone 5' to the AP site, generating a 3'OH and a 5' deoxyribose phosphate (5'dRP) terminus. Subsequently, regular AP sites are repaired via the SP BER pathway whereby the 5'dRP moiety is removed by the dRPase function of Ape1

or DNA Pol β and repair is completed by insertion of the correct base by DNA Pol β and sealing of the nick by DNA ligase III/XRCC1. Modified (oxidized, reduced) and, to a lower extent, regular AP sites, are repaired via LP-BER where DNA polymerase β , δ , or ϵ , along with PCNA and RF-C, fills in a patch of three to eight nucleotides. FEN1 cleaves the displaced stretch of three to eight nucleotides and repair is completed by DNA ligase I or DNA ligase III/XRCC1 (37). Ape1 is essential to complete the repair of AP sites which are generated by the action of different DNA glycosylases on a variety of DNA lesions, including oxidative DNA lesions that can also be excised by the recently identified NEIL glycosylases (5, 53–55, 122). Thus, Ape1 is functionally involved in the short-patch and long-patch BER pathways. As discussed above, Ape1 has a strong 5' AP endonuclease activity, in addition to which it also has a 3'-repair diesterase activity which is important for the removal of 3' blocking lesions generated as a result of the β -lyase function of DNA glycosylases involved in the repair of oxidative or radiation-induced DNA damage (20, 37, 42, 104). Blocking lesions such as 3'-phosphate groups and 3'-phosphoglycolate moieties generated by the action of oxidative agents such as bleomycin, radiation (IR), and also formed at single-strand breaks are removed by Ape1's 3'-phosphodiesterase function so that the subsequent steps of BER can take place and repair can be completed (19, 20, 99, 104, 124). In addition to its hydrolytic and 3'-diesterase functions, Ape1 also has a 3'-5' exonuclease activity which is important to process 3' mispaired termini (22) and for the removal of unnatural nucleoside analogs (21, 23).

AP sites formed as a result of the action of DNA glycosylases can also be generated by spontaneous base hydrolysis in the cell (100), and Ape1 is required to further process these AP sites in order to complete repair. If left unrepaired, these AP sites can be cytotoxic and mutagenic as they can block the replicating polymerase (87, 132, 141). Thus, although AP sites can be generated by the action of several different damage specific DNA glycosylases, only Ape1 can process these AP sites and facilitate repair, thus emphasizing its significance in the BER pathway. Furthermore, importance of Ape1 to normal cellular functioning is highlighted by the embryonic lethality of Ape1 knockout mice (80, 138). Elevated levels of Ape1 in cancer cells have been postulated to be a reason for chemotherapeutic resistance (15, 37, 75, 77, 109, 114, 121, 130) and inhibition of Ape1 has been shown to increase cell killing and apoptosis and also sensitize cancer cells to chemotherapeutic agents. Inhibition of Ape1 using DNA antisense and RNA interference technology is known to increase cell killing and apoptosis and also sensitize cancer cells to chemotherapeutic agents (14, 81, 102, 129). These findings demonstrate the uniqueness of Ape1 as a molecular target in therapeutics.

Other repair functions of Ape1

The multifunctional Ape1 protein has several other functions accompanying its DNA repair and redox regulatory activities. As part of its DNA repair activity, Ape1 removes 3' blocking lesions generated by DNA glycosylases which recognize oxidative damage (Ogg1, Neil) (33, 37, 54) via its 3'-phosphodiesterase and 3'-phosphatase activities to facilitate complete repair. Ape1 also possesses a 3'-5' exonuclease ac-

tivity which is important for the removal of deoxyribonucleoside analogs which can impede repair (19, 22, 23, 34). In addition to the afore mentioned functions, Ape1 has been shown to inhibit the activation of PARP1 (poly(ADP-ribose)polymerase 1) during oxidative damage repair, thus preventing the cells from undergoing apoptosis (105). A relationship between Bcl2 and Ape1 resulting in decreased repair has been reported (72) in addition to negatively regulating the parathyroid hormone gene (PTH) (13, 25, 78, 101), being involved in granzyme A (Gzma) aided NK cell-mediated killing (39, 93) and it has been implicated in nucleotide incision repair (NIR) (65, 66). Ape1 has also been suggested to play a role in negatively regulating the Rac1/GTPase to prevent oxidative stress (103) and to regulate vascular tone and endothelial NO production (71) (Fig. 2).

The redox function of Ape1

In addition to the AP endonuclease function of Ape1, it also functions as a reduction/oxidation (redox) signaling factor (Fig. 3) and is therefore also referred to as Redox effector factor-1 (Ref-1) in the literature (1, 2, 135, 136). Ref-1 reduces key cysteine residues located in the DNA binding domains of transcription factors such as AP1 (Fos/Jun), p53, HIF-1 α , and others (3, 36, 48, 62, 63, 79, 96, 125, 126, 135, 136, 140). This reduction of the critical cysteines in the DNA binding domains of the transcription factors increases their DNA binding ability. Increased DNA binding ability of these transcription factors activates them which leads to the transcription of several key genes important for cell survival and in cancer promotion and progression (37, 124). Thus, the multifunctional Ape1 protein not only functions in and interacts with the proteins involved in the repair of damaged DNA, it also interacts with proteins involved in growth signaling pathways and pathways known to be involved in tumor promotion and progression. The redox function of Ape1 as a target in cancer has not been as extensively investigated as the DNA repair function of Ape1. However, given its role in activating transcription factors such as NF κ B, AP-1, and HIF-1 α etc, inhibiting the redox ability of Ape1 should lead to decreased signaling via these transcription factors of the signaling pathways involved in cancer promotion and progression.

The repair and redox functions of Ape1 are distinct from each other

As discussed previously, Ape1 is a multifunctional protein with roles in DNA repair as well as in redox signaling


in the cell. These two important functions of Ape1 are functionally distinct from each other and are encoded by distinct regions of the protein (137). The AP endonuclease or DNA repair activity which is a critical component of the BER pathway resides in the C-terminal portion of the protein. The AP endonuclease activity is mediated by the active site residues His 309, Glu 96, Asp 238, and Asp 308, where H309 is the catalytic residue (6–8, 11, 37, 45, 50, 88, 98). The redox regulatory activity of Ape1 which is important for the control transcription factors resides in the N-terminal sequences of the protein and a conserved Cys 65 residue is crucial for this function of Ape1 (9, 35, 37, 45). These two important functions of Ape1 can be functionally separated from each other, and disruption of one of its activities does not affect the other. Several reports have shown that disruption of Cys 65 by site-directed mutagenesis (21, 35) or by using a redox specific inhibitor, impairs the redox function of Ape1 but does not affect its DNA repair ability (112, 143).

Ape1 is ubiquitously expressed and though there are several reports showing that Ape1 is localized to the nucleus, cytoplasmic localization of Ape1 has also been reported (34, 74, 97, 113, 134). In addition to exhibiting a heterogeneous and complex pattern of staining, localization of Ape1 is tissue specific and even differs between neighboring cells (113, 134). Localization of Ape1 in the cytoplasm may be associated with its role as a mitochondrial DNA repair protein (37, 97, 124). Noting Ape1's role in redox control of transcription factors, presence of Ape1 in the cytoplasm may be important to maintain these transcription factors in a reduced state prior to their transport to the nucleus (34). Ape1 has also been shown to accumulate in the nucleus and mitochondria in response to DNA damage (97). Thus, it appears that the intracellular localization of Ape1 is regulated; however the significance of its subcellular localization is still not well understood.

Inhibition of DNA Repair as a Target in Cancer

DNA repair pathways are important to maintain the genomic integrity as highlighted by several cancer predisposing syndromes which harbor germline mutations in DNA repair genes (24, 44, 59). Currently, chemotherapy and radiation therapy are the mainstream treatment options available to treat cancers. The cytotoxic effects of most chemotherapeutic agents and radiation are related to their ability to induce DNA damage. The ability of cancer cells to identify and efficiently repair such DNA damage undermines the ef-

FIG. 2. The complex network of protein–protein interactions of Ape1. Ape1 is a multifunctional protein with a role in DNA repair to maintain genomic integrity and a function in cellular redox signaling to activate key transcription factors, leading to changes in expression of genes involved in crucial cellular processes. In addition to these functions, Ape1 interacts with several different proteins from the BER pathway and other DNA repair and signaling pathways to create a complex mesh of direct and indirect interactions. This matrix is a graphical representation of the molecular relationships between genes or gene products (proteins or complexes). Each gene or protein is represented as a *node* and the *lines (edges)* joining them represent the biological relationships between them. At least one reference from the literature, from a textbook, or from canonical information stored in the Ingenuity knowledge base corroborates each edge. Orthologs of a gene (human, mouse, and rat) are represented as a single node in the network but are stored as separate objects in the Ingenuity knowledge base. The various shapes of the nodes represent the functional class of that gene product. The nature of an edge is descriptive of the nature of the relationship between the nodes (*e.g.*, *solid line* indicates a direct relationship, *dashed line* indicates an indirect relationship, etc). This interaction network was generated through the use of Ingenuity Pathways Analysis (Ingenuity Systems®, www.ingenuity.com). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).






FIG. 3. Role of Ape1 in DNA repair and redox regulation. Ape1 is a multifunctional protein that plays an important role in the repair of damaged DNA to maintain genomic integrity. Imbalancing or disrupting the DNA repair ability of Ape1 can lead to an accumulation of mutations and eventually result in death. In addition to Ape1's role in repair of damaged bases, it also plays a role in cellular redox regulation where it functions as a reduction–oxidation (redox) factor and is also known as Ref-1. Ape1 reduces critical cysteine residues in the DNA binding domains of several key transcription factors such as p53, NFκB, AP1, increasing their DNA binding ability which results in a change in the expression of genes involved in key cellular processes.

ficacy of these agents (111, 127). Therefore, inhibiting DNA repair proteins leading to reduced repair of damaged DNA in cancer cells is an attractive approach to combat chemotherapeutic resistance and to increase efficacy of therapy. Although it may sound contradictory to inhibit DNA repair pathway proteins, since cancer promotion and deregulated cellular growth is aided by deficient DNA repair pathways, it actually makes sense to block DNA repair, given the predominance of DNA damage during cancer treatments with chemotherapy and IR, which would allow for increased efficacy of the DNA damaging agent (12, 92). Thus, inhibiting specific proteins from selected DNA repair pathways in cancer cells could provide us with a selective way to sensitize cancer cells to chemotherapeutic agents and also combat their resistance to chemotherapeutic agents (90, 92).

Consequences of inhibiting the BER pathway in cancer

The BER pathway is responsible for repairing DNA damaged by endogenous and exogenous agents including chemotherapeutic agents. In addition to repairing damaged lesions, the proteins of the BER pathway exhibit several important protein–protein and DNA–protein interactions (38) and a delicate balance exists between the levels of all the BER proteins (49). In cancer cells, the upregulation of the BER proteins results in imbalanced repair and can lead to resistance to

chemotherapeutic agents; modulating or inhibiting the activities of these BER proteins can lead to deregulated repair, resulting in sensitivity to chemotherapy agents. However, the central idea that presence of robust DNA repair mechanisms leads to resistance to chemotherapeutic agents (12, 26, 31, 56, 82, 92, 120) has been challenged by some studies. Roth *et al.* (116) showed that absence of Aag (3MeA DNA glycosylase) in the bone marrow (BM) cells of the myeloid lineage from *Aag*^{-/-} mice are resistant to alkylating agents (MMS), as compared to the wild-type BM cells. They speculated that initiation of repair by Aag and subsequent incomplete repair of the lesions in wild-type BM cells may be more toxic than the inability of *Aag* null BM cells to initiate repair of these damaged lesions. This effect was specific to the myeloid lineage of the *Aag*^{-/-} mice and was not observed in embryonic stem cells (ES), primary embryonic fibroblasts (PEF) and cells from the lymphoid lineage in the BM, indicating that this effect is tissue specific, as well as likely lesion specific. In general, it has been shown that presence of DNA repair contributes to resistance to chemotherapeutic agents. DNA glycosylases show quite a bit of functional redundancy (80), and the action of all the DNA glycosylases results in the formation of AP sites. For instance, overexpression of 3MeA DNA glycosylases in *S. cerevisiae* and *E. coli* leads to increased sensitivity to alkylating agents and spontaneous mutations, possibly due to an imbalance between the levels of the DNA glycosylase and Ape1 proteins and also




FIG. 4. Consequences of inhibiting Ape1 and BER. DNA glycosylases initiate BER and their action results in the formation of AP sites. These AP sites are further processed by Ape1. However, failure to complete the repair of these AP sites cause them to accumulate and such accumulated AP sites can lead to cytotoxicity and increased apoptosis. High levels of Ape1 in cancer cells have been linked to resistance to chemotherapy, poor prognosis, and survival. Thus, inhibiting Ape1 leads to sensitization of cancer cells to chemotherapeutic agents.

due to the build-up of unrepaired AP sites (116). Accumulation of these unrepaired AP sites can lead to (Fig. 4) single-strand breaks, increased apoptosis, and enhanced cytotoxicity (47). Ape1 is required to process these AP sites and along with the rest of the BER proteins can facilitate the ensuing completion of repair. Increased expression of the BER pathway proteins in cancer cells can result in efficient repair of damaged lesions and can reduce the effectiveness of chemotherapeutic agents. Therefore, keeping in mind the importance of the BER pathway in the repair of damage induced by chemotherapy, exploiting the BER pathway and its proteins by inhibiting them would increase the efficacy of chemotherapy, thus making it an attractive target to develop novel means in order to combat chemotherapeutic resistance (120).

Inhibition of the DNA Repair Function of Ape1 as a Rational Cancer Target

There are several reasons why Ape1 is a rational target for chemotherapeutic agents: (a) overexpression of Ape1 leads to chemoresistance; (b) cells that lack Ape1 are not viable; (c) knockdown or blockage of Ape1 activity sensitizes cancer cells to chemo agents such as temozolomide (TMZ) and bleomycin. Elevated levels of Ape1 in cancer cells have been postulated to be a reason for chemotherapeutic resistance (14, 37, 75, 77, 109, 114, 121, 130). The importance of Ape1's function in the DNA BER pathway is observed from the lethality of Ape1 knockout mice (80, 138). Specifically knock-

ing down or inhibiting Ape1 using RNA interference and anti-sense oligonucleotide technology hypersensitizes mammalian cancer cells to several laboratory and clinical DNA damaging agents, such as methyl methane sulfonate (MMS), hydrogen peroxide (H_2O_2), bleomycin, TMZ, and gemcitabine (14, 15, 75, 81, 87, 114, 121, 129, 130). The decrease in cancer cell proliferation and survival after knocking down Ape1 reiterates the importance of Ape1 function. Although these data demonstrate Ape1 is a feasible target for inhibition to sensitize cancer cells, studies involving a reduction in Ape1 mRNA and protein do not allow us to dissect which function, repair or redox, of Ape1 is important for cell growth, cancer promotion and/or progression (14, 15, 75, 81, 87, 114, 121, 129, 130). Fung *et al.* (47) demonstrated that depletion of Ape1 from cells using siRNA technology causes increased apoptosis and decreased cell growth of cancer cells. They further demonstrated that functional complementation with a yeast homologue (Ape1) of Ape1 deficient in redox activity could restore proliferation potential of the cells. Another report demonstrated that expressing a dominant-negative repair deficient Ape1 protein in cells sensitizes them to chemotherapeutic agents (94). Several studies conducted using a small molecule that binds to AP sites in DNA [methoxyamine (MX)] and blocks Ape1's ability to cut the sugar-phosphate backbone sensitized cancer cells to chemotherapeutic agents (41, 84, 85, 123). Conversely, as we learn more about the redox function of Ape1, we appreciate its critical role in cell growth. Another recent study demon-




FIG. 5. Dose response with NCA in the gel-based AP endonuclease assay. (A) Determination of NCA to inhibit Ape1's DNA repair activity in the gel-based AP endonuclease assay. Pure Ape1 protein at a concentration of 0.0875 nM was incubated with increasing amounts of NCA, appropriate buffers (5 mM HEPES, 5 mM KCl, 1 mM MgCl₂, 1% BSA, and 0.05% Triton X-100, pH 7.5) and a double-stranded oligonucleotide substrate labeled with hexachloro-fluorescein phosphoramidite label (HEX) with a tetrahydrofuran (THF) moiety at a concentration of 12.5 nM. Reactions were incubated at 37°C for 15 min and were terminated by the addition of 10 μl of formamide without dyes. Presence of Ape1 in the reactions results in the cleavage of the THF moiety. Resolution of the samples on a 20% denaturing gel with 7 M urea results in two bands. The slower *upper band* corresponds to the full length, labeled and uncleaved oligonucleotide (26 mer), and the faster running *lower band* (14 mer) corresponds to the shorter labeled cleaved fragment, which is indicative of Ape1's cleavage activity. The gel is of a representative AP endonuclease assay with varying amounts of NCA. (B) This is a quantitation of the gel-based AP endonuclease assay results with concentration of NCA graphically represented

against its % activity as a histogram. Shown here is the average of three experiments. The error bars represent standard error. P values were calculated using Student's *t* test, comparing lanes with inhibitor to lane with no inhibitor. The values were not found to be statistically significant.

strated that the redox function of Ape1 is important in hematopoietic differentiation (growth) by using a specific inhibitor of Ape1's redox activity, but did not cause the cells to undergo apoptosis (143). These observations not only suggest a crucial role for both of Ape1's functions in cellular survival and tumor promotion and progression, but also demonstrate differences observed when the redox or repair functions are blocked. Developing specific inhibitors of the two functions of Ape1 would further allow us to discern which of the activities of Ape1 are important for cancer promotion and progression and normal cellular survival. Furthermore, the two functions may play different roles in different kinds of cancer, allowing us to better understand tumor progression. Thus, the consequences of inhibiting of Ape1 in cancer cells point to it being a logical target in cancer therapeutics. Identification of molecules that specifically inhibit Ape1's repair or redox activity should be an effective means to sensitize cancer cells to chemotherapeutic agents and thus impact the development of new and targeted cancer therapies. This review will focus on repair inhibition (see review for information on redox inhibitors) (42).

Existing Ape1 DNA Repair Inhibitors

As discussed above, Ape1's importance in the BER pathway and unique role supports the hypothesis that it is a strong target for cancer therapy; elevated levels in cancer cells and knocking down Ape1 using siRNA leads to in-

creased ability of cancer cells to undergo apoptosis and sensitization to chemotherapeutic agents (14, 37, 75, 77, 109, 114, 121, 130). Thus, combining standard chemotherapeutic strategies with targeted inhibitors of Ape1's DNA repair function would increase the effectiveness of existing chemotherapeutic regimens. Currently three compounds are known to inhibit Ape1's DNA repair activity, methoxyamine (MX) and two compounds, CRT0044876 or 7-nitroindole-2-carboxylic acid (NCA) (91), and an arylstibonic acid compound (118), both identified in high throughput screening (HTS) assays.

Methoxyamine (MX), an indirect inhibitor of Ape1's repair activity

Methoxyamine (MX) is an inhibitor of Ape1 which interacts with the aldehydic C1 atom left at the DNA abasic site after removal of the damaged base by a DNA glycosylase (86). MX is considered to be an indirect inhibitor of Ape1 in that it does not directly bind to Ape1 and inhibit its activity. Rather, MX binds to AP sites and prevents Ape1 and Pol β from processing them further and completing repair. As a single agent, MX is not significantly cytotoxic, however MX can potentiate the cytotoxicity of alkylating agents such as TMZ and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (41, 84, 123). TMZ predominantly alkylates guanine at the N7 and O6 positions and adenine at the N3 position. The BER pathway repairs N7 and N3 alkylation damage and the ac-




FIG. 6. Optimization of the Ape1 high throughput screening assay. Pure Ape1 protein was tested in a range of concentrations from 0.075 to 1.4 nM. The increase in fluorescence over of time was determined for each concentration of Ape1. Based on analysis of the linear range and magnitude of fluorescent signal, a concentration of 0.35 nM Ape1 was selected for the HTS assay. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).

tion of the DNA glycosylases generate AP sites. MX binds to these AP sites, thus preventing Ape1 from completing the repair and stabilizing the AP site intermediate (41, 84, 123). Clinical trials with MX in combination with TMZ are currently being pursued. A direct repair inhibitor with the ability to directly block Ape1's repair activity should prove to be more potent in sensitizing cells to chemotherapeutic alkylating agents while reducing nonspecific effects. As discussed previously, MX is currently in use to block Ape1's ability to repair AP sites. However, this reagent targets the DNA (AP sites) and not Ape1 directly (86, 115). MX stably interacts with the C1' aldehyde atom resulting from the removal of the damaged base, producing a stable covalent adduct (86); Ape1 is unable to readily cleave the resulting MX-AP site (46). MX is a simple compound, H_3CONH_2 , with no obvious potential for improvement in efficacy through derivatization and high concentrations of MX are required in cell-based assays (20–50 mM) in order to potentiate cell killing in combination with other agents (85, 94, 123, 139). In addition, since MX binds AP sites and not Ape1 directly, it will also affect the ability of other mammalian enzymes to bind DNA substrates including DNA Pol β (61).

Lucanthone, a direct inhibitor of Ape1's repair activity

Lucanthone, originally identified as a topoisomerase II poison (10), is considered to be a direct inhibitor of Ape1's DNA repair activity. Its extensive use to treat schistosomiasis has shown it to be safe and nearly nontoxic from a clinical standpoint (28). Cancer cells treated with lucanthone ex-

hibited a dose-dependent increase in AP sites, seemingly due to inhibition of Ape1's repair activity and blocking an early step in the BER pathway (95). Patients with brain metastasis treated in combination with radiation and lucanthone showed increased regression of the tumors with the combination, as compared to radiation alone (28). Additionally, lucanthone enhances the cell killing effect of MMS and TMZ in breast cancer cells by the inhibition of Ape1's DNA repair activity (89). However, the evidence of lucanthone, also being a topoisomerase II inhibitor, raises the concern that the tumor cell killing observed could be partially attributed to the off-target effects of lucanthone, which again points to the need of a robust direct inhibitor of Ape1's repair function.

7-Nitroindole-2-carboxylic acid (NCA), a direct inhibitor of Ape1's repair activity

Madhusudhan *et al.* (91) identified CRT0044876 or 7-nitroindole-2-carboxylic acid (NCA) in a high-throughput screen (HTS) of a library of 5,000 drug-like compounds to be a direct inhibitor of Ape1's repair activity with an IC_{50} value of $\sim 3 \mu\text{M}$. NCA is negatively charged and is reported to inhibit all the DNA repair activities of Ape1 such as the AP endonuclease (repair activity), 3'-phosphodiesterase, 3'-5' exonuclease, and 3'-phosphatase activities of Ape1. Survival analyses in HT1080 human fibrosarcoma cells showed that NCA potentiates the cytotoxicity of MMS, TMZ, H_2O_2 , and zeocin (91). However, efforts to reproduce this repair inhibition have not been realized by our laboratory and by others (51) (Fig. 5A and B).




FIG. 7. Scatter plot for the Z' factor measurement. This is a scatter plot of the positive and negative control data for Ape1 HTS assay. The Z' factor for the assay was calculated from the formula described by Zhang *et al.* (141). The Z' factor calculated for this assay is 0.78.

Arylstibonic acid compounds as inhibitors of Ape1's repair activity

Recently, Seiple *et al.* (118) screened an NCI Diversity Set library of 2,000 compounds to identify specific inhibitors of Ape1. The authors identified an arylstibonic acid compound 13755 which has a negative charge, as an inhibitor of Ape1's DNA repair activity. This compound shows partial mixed type inhibition in that it binds both to the enzyme and the enzyme substrate complex. Even though these compounds have been reported to inhibit Ape1's DNA repair activity *in vitro*, they have virtually no cellular uptake and are less attractive as translational agents. Treatment of HOS osteosarcoma cells with 5 μ M of the compound in the presence of MMS did not show decreased survival in cytotoxicity assays (118).

Need for Specific Inhibitors of Ape1's DNA Repair Activity

There is a clear need for a specific repair inhibitor of Ape1 in order to effectively determine the role of Ape1's repair activity in potentiating the effects of alkylating chemotherapeutic agents. This is required given the importance of inhibiting Ape1 using siRNA leading to sensitization of cancer cells to chemotherapeutic agents (14, 15, 75, 81, 87, 114, 121, 129, 130). However, these studies remove *all* of Ape1's functions (repair and redox) as well as Ape1's protein-protein interactions (38), making the data difficult to interpret. Thus, identifying specific and potent Ape1 repair inhibitors would facilitate the understanding of Ape1 not only in cancer, but also in dividing normal cells (bone marrow, gut, etc), non-dividing normal cells (neurons), and other diseases where

Ape1 has been implicated (17, 47, 60, 67, 106, 124). In addition, these small molecule inhibitors will allow the specific inhibition of Ape1's repair function while keeping its post-translational modifications (18, 68, 70, 97) and subcellular location of Ape1 intact and in determining the effect of blocking Ape1's function on these subcellular events (30, 107, 124). In summary, identification of specific inhibitors of Ape1's repair activity will further our ability to determine the role it plays in cancer promotion and progression, thus making a productive target of chemoprevention.

High Throughput Screening (HTS) Methodology to Identify Specific Inhibitors of Ape1's DNA Repair Activity

High throughput screening (HTS) is an efficient scientific method that allows the assay of large numbers of varied chemical compounds against biological targets in a relatively short period of time. HTS assays are either entirely or partially automated and can be carried out in the 96-well or 384-well format. Robotic automation in HTS helps speed up the process of drug discovery and facilitates the generation of a large amount of scientific data in a short time-frame. Several different libraries of synthetic and drug-like compounds are available for HTS. Typically, the first round of HTS is carried out with a fixed concentration (1–10 μ M) of the chemical compound. The positive 'hits' identified in the primary assay can be re-screened in the same assay and these hits are then followed up in secondary assays to validate them, determine an IC₅₀ concentration, and perform functional cellular assays. Thus, HTS is a promising and rapid methodol-




FIG. 8. Dose response with HTS compound AB-01 in the gel-based AP endonuclease assay. (A) The ability of the HTS compound AB-01 to inhibit Ape1's DNA repair activity in the gel-based AP endonuclease assay was determined. 0.0875 nM concentration of pure Ape1 protein was incubated with increasing amounts of AB-01, appropriate buffers (5 mM HEPES, 5 mM KCl, 1 mM MgCl₂, 1% BSA, and 0.05% Triton X-100, pH 7.5) and a double-stranded hexachloro-fluorescein phosphoramidite labeled (HEX) oligonucleotide substrate with a tetrahydrofuran (THF) moiety at a concentration of 12.5 nM. Reactions were incubated at 37°C for 15 min and were terminated by the addition of 10 μ l formamide without dyes. Ape1 in the reaction cleaves the THF moiety and resolution of the samples on a 20% denaturing gel with 7 M Urea results in two bands. The slower *upper band* corresponds to the full length, labeled, and uncleaved oligonucleotide (26 mer) and the faster running *lower band* (14 mer) corresponds to the shorter labeled cleaved fragment, which is indicative of Ape1's cleavage activity. The gel is of a representative AP endonuclease assay with varying amounts of AB-01. (B) This is a quantitation of the gel-based AP endonuclease assay results with concentration of AB-01 graphically represented against its % activity as a histogram. Shown here is the average of three experiments and the *error bars* represent standard error. *P* values were calculated using Student's *t*-test, comparing lanes with inhibitor to lane with no inhibitor (**p* < 0.05 and ***p* < 0.01).

ogy to identify potential modulators of the biological activity of the target from a large number of compounds.

Efforts are under way in our laboratory to identify and develop a novel inhibitor of Ape1's DNA repair activity using the HTS methodology. We have modified the fluorescence-based high throughput screening assay described by Madhusudhan *et al.* (91) to screen a library of 60,000 synthetic drug-like compounds which follow Lipinsky's rule of five (83) from Chemical Diversity Ltd Inc. (San Diego, CA). We used purified Ape1 protein at a concentration that showed a linear range for the assay over a period of time (Fig. 6). In order to determine the reliability of the assay, we performed control experiments and calculated the Z'-factor score of 0.78

(Fig. 7). The Z'-factor reflects the dynamic range between the positive and negative controls and is also a reflection of the reproducibility of the data and reliability of the assay. The Z'-factor values range from 0.5 to 1.0, and a score above 0.5 is an indication of a good assay, with 1 being a perfect assay (142). After an initial screen of the 60,000 compound library, we identified 190 compounds showing $\geq 50\%$ inhibition of Ape1's DNA repair activity. Of the 190 compounds, 174 were available and re-screened in the same HTS assay. Forty-five compounds showing $\geq 40\%$ inhibition of Ape1's repair activity were identified after two rounds of HTS screening. These 45 compounds are now being further validated in a secondary gel-based AP endonuclease assay to

further assess inhibition of the compounds. On completion of the validation of the 45 compounds in the secondary assays, promising compounds will then be tested for their ability to specifically inhibit Ape1's DNA repair ability in *in vitro* cellular assays, including cell growth, cytotoxicity, and apoptosis assays.

In the secondary gel-based AP endonuclease assay, a concentration of Ape1 protein in the linear range was titrated against a range of concentrations of the compounds. As a control, all the compounds tested in the gel-based AP endonuclease assay are compared to NCA, a known inhibitor of Ape1's DNA repair activity, at a concentration of 10 μ M (91). One of the compounds identified in the HTS screen, AB-01, demonstrated consistent inhibition of Ape1's DNA repair activity both in the HTS and the secondary gel-based AP endonuclease assay. As seen in Fig. 8A and B, compound AB-01 is able to inhibit Ape1's DNA repair activity. At a concentration of 10 μ M, inhibition of Ape1's DNA repair activity by AB-01 is better than that demonstrated by NCA at the same concentration.

Conclusions

Ability of cancer cells to recognize and repair chemotherapy-induced damage is an important factor in resistance to chemotherapy (90). Therefore, inhibiting DNA damage repair pathways and using inhibitors against specific proteins of these pathways is an excellent strategy to develop targeted therapies for cancer treatment. (12, 31, 59, 90, 92). Ape1 is an essential protein functioning in the BER pathway which repairs damage caused by endogenous as well as exogenous DNA base damage including chemotherapy-induced DNA damage (24, 37, 44). Ape1 is unique such that it is the only cellular protein that can process the AP sites generated as a result of the action of the DNA glycosylases. It is also the **only** DNA repair and redox protein in the cells and there is no backup for the critically important repair function of Ape1 in cancer cells. This makes it a unique target, particularly since it has two important functions that work independently of one another. In addition to its important role in normal cellular functioning, altered or elevated levels of Ape1 have been observed in a variety of cancers, including breast cancer, gliomas, sarcomas (osteosarcomas, rhabdomyosarcomas), ovarian and multiple myeloma, among others (37, 75, 77, 109, 114, 121, 130) which have been speculated to be a cause of resistance to chemotherapy. In addition, these heightened levels of Ape1 have been linked to tumor promotion, progression, and poor prognosis associated with shorter relapse-free survival and poor outcome from chemotherapy (77). There is a vast amount of data showing that downregulating or inhibiting Ape1 in cancer cells using RNA interference and DNA antisense oligonucleotide techniques can sensitize them to laboratory and clinical chemotherapeutic agents (14, 15, 75, 81, 114, 121, 129, 131). Since Ape1 is involved in the repair of DNA damaged by chemotherapeutic agents, identifying selective inhibitors of the DNA repair or redox activities of Ape1 would make it an excellent target, both from a single agent approach and in combination with chemotherapy and IR. Additionally, it may be coupled with other specific molecular targets in cell cycle or other pathways to thwart the cancer cell from skirting cell death and prevent drug resistance from occurring.

Acknowledgments

Financial support for this work was provided by the National Institutes of Health, National Cancer Institute CA94025, CA106298, CA114571, and CA121168 to MRK, IU Simon Cancer Center Translational initiative pilot funding (ITRAC) to MRK, and the Riley Children's Foundation (MRK).

Abbreviations

AAG, 3Me A DNA glycosylase; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; 5' dRP, 8-oxoG, 8-oxo-7,8-dihydroguanine; OGG1, 8-oxoguanine DNA glycosylase; Ape1, apurinic/apyrimidinic endonuclease 1; AP sites, apurinic/apyrimidinic sites; BER, base excision repair, NCA, CRT0044876 7-nitroindole, 2-carboxylic acid; DNA Pol β , DNA polymerase β ; ES, embryonic stem; Fen-1, flap endonuclease-1; Gzm A, granzyme A; HTs, high throughput screen; HR, homologous recombination; H₂O₂, hydrogen peroxide; IR, ionizing radiation; ITRAC, IU Simon Cancer Center Translational Research Acceleration Collaboration; LP-BER, long patch-BER; MX, methoxyamine; MMS, methyl methane sulfonate; MMR, mismatch repair; MPG, N-methyl purine DNA glycosylase; NK, natural killer, NEIL, Nei endonuclease VIII like; NO, nitric oxide; NHEJ, non-homologous end joining; NER, nucleotide excision repair; NIR, nucleotide incision repair; PTH, parathyroid hormone; PEF, primary embryonic fibroblasts; PARP, poly (ADP ribose) polymerase 1; Ref-1, redox effector factor-1; SP-BER, short patch-BER; TMZ, temozolomide; XRCC1, x-ray cross complementing factor 1.

References

1. Abate C, Luk D, and Curran T. A ubiquitous nuclear protein stimulates the DNA-binding activity of fos and jun indirectly. *Cell Growth Differ* 1: 455–462, 1990.
2. Abate C, Patel L, Rauscher FJ 3rd, and Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. *Science* 249: 1157–1161, 1990.
3. Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J, and Shigesada K. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues. *J Biol Chem* 272: 14497–14500, 1997.
4. Altieri F, Grillo C, Maceroni M, and Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. *Antioxid Redox Signal* 10: 891–938, 2008.
5. Bandaru V, Sunkara S, Wallace SS, and Bond JP. A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to *Escherichia coli* endonuclease VIII. *DNA Repair (Amst)* 1: 517–529, 2002.
6. Barzilay G and Hickson ID. Structure and function of apurinic/apyrimidinic endonucleases. *Bioessays* 17: 713–719, 1995.
7. Barzilay G, Mol CD, Robson CN, Walker LJ, Cunningham RP, Tainer JA, and Hickson ID. Identification of critical active-site residues in the multifunctional human DNA repair enzyme HAP1. *Nat Struct Biol* 2: 561–568, 1995.
8. Barzilay G, Walker LJ, Robson CN, and Hickson ID. Site-directed mutagenesis of the human DNA repair enzyme HAP1: Identification of residues important for AP endonuclease and RNase H activity. *Nucleic Acids Res* 23: 1544–1550, 1995.

9. Barzilay G, Walker LJ, Rothwell DG, and Hickson ID. Role of the HAP1 protein in repair of oxidative DNA damage and regulation of transcription factors. *Br J Cancer Suppl* 27: S145–S150, 1996.
10. Bases RE and Mendez F. Topoisomerase inhibition by luncanthone, an adjuvant in radiation therapy. *Int J Radiat Oncol Biol Phys* 37: 1133–1137, 1997.
11. Beernink PT, Segelke BW, Hadi MZ, Erzberger JP, Wilson DM 3rd, and Rupp B. Two divalent metal ions in the active site of a new crystal form of human apurinic/aprimidinic endonuclease, Ape1: implications for the catalytic mechanism. *J Mol Biol* 307: 1023–1034, 2001.
12. Belzile JP, Choudhury SA, Cournoyer D, and Chow TY. Targeting DNA repair proteins: A promising avenue for cancer gene therapy. *Curr Gene Ther* 6: 111–123, 2006.
13. Bhakat KK, Izumi T, Yang SH, Hazra TK, and Mitra S. Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. *EMBO J* 22: 6299–6309, 2003.
14. Bobola MS, Emond MJ, Blank A, Meade EH, Kolstoe DD, Berger MS, Rostomily RC, Silbergeld DL, Spence AM, and Silber JR. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. *Clin Cancer Res* 10: 7875–7883, 2004.
15. Bobola MS, Finn LS, Ellenbogen RG, Geyer JR, Berger MS, Braga JM, Mead EH, Gross ME, and Silber JR. Apurinic/aprimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. *Clin Cancer Res* 11: 7405–7414, 2005.
16. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434: 913–917, 2005.
17. Chang IY, Kim SH, Cho HJ, Lee DY, Kim MH, Chung MH, and You HJ. Human AP endonuclease suppresses DNA mismatch repair activity leading to microsatellite instability. *Nucleic Acids Res* 33: 5073–5081, 2005.
18. Chattopadhyay R, Wiederhold L, Szczesny B, Boldogh I, Hazra TK, Izumi T, and Mitra S. Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells. *Nucleic Acids Res* 34: 2067–2076, 2006.
19. Chaudhry MA, Dedon PC, Wilson DM 3rd, Demple B, and Weinfeld M. Removal by human apurinic/aprimidinic endonuclease 1 (Ape 1) and *Escherichia coli* exonuclease III of 3'-phosphoglycolates from DNA treated with neocarzinostatin, calicheamicin, and gamma-radiation. *Biochem Pharmacol* 57: 531–538, 1999.
20. Chen DS, Herman T, and Demple B. Two distinct human DNA diesterases that hydrolyze 3'-blocking deoxyribose fragments from oxidized DNA. *Nucleic Acids Res* 19: 5907–5914, 1991.
21. Chou KM and Cheng YC. The exonuclease activity of human apurinic/aprimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G. *J Biol Chem* 278: 18289–18296, 2003.
22. Chou KM and Cheng YC. An exonucleolytic activity of human apurinic/aprimidinic endonuclease on 3' mispaired DNA. *Nature* 415: 655–659, 2002.
23. Chou KM, Kukhanova M, and Cheng YC. A novel action of human apurinic/aprimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA. *J Biol Chem* 275: 31009–31015, 2000.
24. Christmann M, Tomicic MT, Roos WP, and Kaina B. Mechanisms of human DNA repair: an update. *Toxicology* 193: 3–34, 2003.
25. Chung U, Igarashi T, Nishishita T, Iwanari H, Iwamatsu A, Suwa A, Mimori T, Hata K, Ebisu S, Ogata E, Fujita T, and Okazaki T. The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium. *J Biol Chem* 271: 8593–8598, 1996.
26. Damia G and D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. *Eur J Cancer* 43: 179–1801, 2007.
27. David SS and Williams SD. Chemistry of glycosylases and endonucleases involved in base-excision repair. *Chem Rev* 98: 1221–1262, 1998.
28. Del Rowe JD, Bello J, Mitnick R, Sood B, Filippi C, Moran J, Freeman K, Mendez F, and Bases R. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, luncanthone. *Int J Radiat Oncol Biol Phys* 43: 89–93, 1999.
29. Demple B and Harrison L. Repair of oxidative damage to DNA: enzymology and biology. *Annu Rev Biochem* 63: 915–948, 1994.
30. Di Maso V, Avellini C, Croce LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, and Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: Possible prognostic significance. *Mol Med* 13: 89–96, 2007.
31. Ding J, Miao ZH, Meng LH, and Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems. *Trends Pharmacol Sci* 27: 338–344, 2006.
32. Doetsch PW and Cunningham RP. The enzymology of apurinic/aprimidinic endonucleases. *Mutat Res* 236: 173–201, 1990.
33. Dou H, Mitra S, and Hazra TK. Repair of oxidized bases in DNA bubble structures by human DNA glycosylases NEIL1 and NEIL2. *J Biol Chem* 278: 49679–49684, 2003.
34. Duguid JR, Eble JN, Wilson TM, and Kelley MR. Differential cellular and subcellular expression of the human multifunctional apurinic/aprimidinic endonuclease (APE/ref-1) DNA repair enzyme. *Cancer Res* 55: 6097–6102, 1995.
35. Dyrkheeva NS, Khodyreva SN, and Lavrik OI. Multifunctional human apurinic/aprimidinic endonuclease 1: role of additional functions. *Mol Biol* 41: 402–416, 2007.
36. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1 α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. *EMBO J* 18: 1905–1914, 1999.
37. Evans AR, Limp-Foster M, and Kelley MR. Going APE over ref-1. *Mutat Res* 461: 83–108, 2000.
38. Fan J and Wilson DM 3rd. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. *Free Radic Biol Med* 38: 1121–1138, 2005.
39. Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, and Lieberman J. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. *Nat Immunol* 4: 145–153, 2003.
40. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 434: 917–921, 2005.
41. Fishel ML, He Y, Smith ML, and Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to

- alkylating agent temozolomide. *Clin Cancer Res* 13: 260–267, 2007.
42. Fishel ML and Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. *Mol Aspects Med* 28: 375–395, 2007.
43. Flaherty DM, Monick MM, and Hunninghake GW. AP endonucleases and the many functions of Ref-1. *Am J Repair Cell Mol Biol* 25: 664–667, 2001.
44. Fleck O and Nielsen O. DNA repair. *J Cell Sci* 117: 515–517, 2004.
45. Fritz G. Human APE/Ref-1 protein. *Int J Biochem Cell Biol* 32: 925–929, 2000.
46. Frosina G, Fortini P, Rossi O, Carrozzino F, Abbondandolo A, and Dogliotti E. Repair of abasic sites by mammalian cell extracts. *Biochem J* 304: 699–705, 1994.
47. Fung H and Demple B. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. *Mol Cell* 17: 463–470, 2005.
48. Gaiddon C, Moorthy NC, and Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. *EMBO J* 18: 5609–5621, 1999.
49. Glassner BJ, Rasmussen LJ, Najarian MT, Posnick LM, and Samson LD. Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. *Proc Natl Acad Sci USA* 95: 9997–10002, 1998.
50. Gorman MA, Morera S, Rothwell DG, de La Fortelle E, Mol CD, Tainer JA, Hickson ID, and Freemont PS. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. *EMBO J* 16: 6548–6558, 1997.
51. Guikema JE, Linehan EK, Tsuchimoto D, Nakabeppu Y, Strauss PR, Stavnezer J, and Schrader CE. APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. *J Exp Med* 204: 3017–3026, 2007.
52. Harrison L, Hatahet Z, Purmal AA, and Wallace SS. Multiply damaged sites in DNA: interactions with *Escherichia coli* endonucleases III and VIII. *Nucleic Acids Res* 26: 932–941, 1998.
53. Hazra TK, Izumi T, Boldogh I, Imhoff B, Kow YW, Jaruga P, Dizdaroglu M, and Mitra S. Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA. *Proc Natl Acad Sci USA* 99: 3523–3528, 2002.
54. Hazra TK, Izumi T, Kow YW and Mitra S. The discovery of a new family of mammalian enzymes for repair of oxidatively damaged DNA, and its physiological implications. *Carcinogenesis* 24: 155–157, 2003.
55. Hazra TK, Kow YW, Hatahet Z, Imhoff B, Boldogh I, Mokkapati SK, Mitra S and Izumi T. Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions. *J Biol Chem* 277: 30417–30420, 2002.
56. Helleday T, Petermann E, Lundin C, Hodgson B, and Sharma RA. DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer* 8: 193–204, 2008.
57. Hilbert TP, Boorstein RJ, Kung HC, Bolton PH, Xing D, Cunningham RP, and Teebor GW. Purification of a mammalian homologue of *Escherichia coli* endonuclease III: identification of a bovine pyrimidine hydrate-thymine glycol DNase/AP lyase by irreversible cross linking to a thymine glycol-containing oligonucleotide. *Biochemistry* 35: 2505–2511, 1996.
58. Hilbert TP, Chaung W, Boorstein RJ, Cunningham RP, and Teebor GW. Cloning and expression of the cDNA encoding the human homologue of the DNA repair enzyme, *Escherichia coli* endonuclease III. *J Biol Chem* 272: 6733–6740, 1997.
59. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. *Nature* 411: 366–374, 2001.
60. Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, and Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. *J Clin Invest* 112: 1887–1894, 2003.
61. Horton JK, Prasad R, Hou E, and Wilson SH. Protection against methylation-induced cytotoxicity by DNA polymerase beta-dependent long patch base excision repair. *J Biol Chem* 275: 2211–2218, 2000.
62. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. *J Biol Chem* 271: 32253–32259, 1996.
63. Huang RP and Adamson ED. Characterization of the DNA-binding properties of the early growth response-1 (Egr-1) transcription factor: evidence for modulation by a redox mechanism. *DNA Cell Biol* 12: 265–273, 1993.
64. Ikeda S, Biswas T, Roy R, Izumi T, Boldogh I, Kurosky A, Sarker AH, Seki S, and Mitra S. Purification and characterization of human NTH1, a homolog of *Escherichia coli* endonuclease III. Direct identification of Lys-212 as the active nucleophilic residue. *J Biol Chem* 273: 21585–21593, 1998.
65. Ischenko AA and Sapparbaev MK. Alternative nucleotide incision repair pathway for oxidative DNA damage. *Nature* 415: 183–187, 2002.
66. Ishchenko AA, Deprez E, Maksimenko A, Brochon JC, Tauc P, and Sapparbaev MK. Uncoupling of the base excision and nucleotide incision repair pathways reveals their respective biological roles. *Proc Natl Acad Sci USA* 103: 2564–2569, 2006.
67. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, Yasue T, Lee KM, Kang D, Yoo KY, Sato S, Ueda R, and Tajima K. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. *Carcinogenesis* 25: 1395–1401, 2004.
68. Izumi T, Brown DB, Naidu CV, Bhakat KK, Macinnes MA, Saito H, Chen DJ, and Mitra S. Two essential but distinct functions of the mammalian abasic endonuclease. *Proc Natl Acad Sci USA* 102: 5739–5743, 2005.
69. Izumi T, Wiederhold LR, Roy G, Roy R, Jaiswal A, Bhakat KK, Mitra S, and Hazra TK. Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage. *Toxicology* 193: 43–65, 2003.
70. Jackson EB, Theriot CA, Chattopadhyay R, Mitra S, and Izumi T. Analysis of nuclear transport signals in the human apurinic/apyrimidinic endonuclease (APE1/Ref-1). *Nucleic Acids Res* 33: 3303–3312, 2005.
71. Jeon BH, Gupta G, Park YC, Qi B, Haile A, Khanday FA, Liu YX, Kim JM, Ozaki M, White AR, Berkowitz DE, and Irani K. Apurinic/apyrimidinic endonuclease 1 regulates endothelial NO production and vascular tone. *Circ Res* 95: 902–910, 2004.
72. Jin Z, May WS, Gao F, Flagg T, and Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. *J Biol Chem* 281: 14446–14456, 2006.
73. Johnson RE, Torres-Ramos CA, Izumi T, Mitra S, Prakash S and Prakash L. Identification of APN2, the *Saccharomyces*

- cerevisiae* homolog of the major human AP endonuclease HAP1, and its role in the repair of abasic sites. *Genes Dev* 12: 3137–3143, 1998.
74. Kakolyris S, Kaklamanis L, Giatromanolaki A, Koukourakis M, Hickson ID, Barzilay G, Turley H, Leek RD, Kanavaros P, Georgoulas V, Gatter KC, and Harris AL. Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human disease. *Histopathology* 33: 561–569, 1998.
 75. Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, Broshears J, and Koch M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. *Clin Cancer Res* 7: 824–830, 2001.
 76. Kennedy RD and D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. *J Clin Oncol* 24: 3799–3808, 2006.
 77. Koukourakis MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulas V, Funtzilas G, Hickson ID, Gatter KC, and Harris AL. Nuclear expression of human apurinic/aprimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. *Int J Radiat Oncol Biol Phys* 50: 27–36, 2001.
 78. Kuninger DT, Izumi T, Papaconstantinou J, and Mitra S. Human AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor element in the AP-endonuclease 1 promoter. *Nucleic Acids Res* 30: 823–829, 2002.
 79. Lando D, Pongratz I, Poellinger L, and Whitelaw ML. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1 α and the HIF-like factor. *J Biol Chem* 275: 4618–4627, 2000.
 80. Larsen E, Meza TJ, Kleppa L, and Klungland A. Organ and cell specificity of base excision repair mutants in mice. *Mutat Res* 614: 56–68, 2007.
 81. Lau JP, Weatherdon KL, Skalski V, and Hedley DW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. *Br J Cancer* 91: 1166–1173, 2004.
 82. Lieberman HB. DNA damage repair and response proteins as targets for cancer therapy. *Curr Med Chem* 15: 360–367, 2008.
 83. Lipinski C and Hopkins A. Navigating chemical space for biology and medicine. *Nature* 432: 855–861, 2004.
 84. Liu L, Nakatsuru Y, and Gerson SL. Base excision repair as a therapeutic target in colon cancer. *Clin Cancer Res* 8: 2985–2991, 2002.
 85. Liu L, Yan L, Donze JR, and Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. *Mol Cancer Ther* 2: 1061–1066, 2003.
 86. Liuzzi M and Talpaert-Borle M. A new approach to the study of the base-excision repair pathway using methoxyamine. *J Biol Chem* 260: 5252–5258, 1985.
 87. Loeb LA and Preston BD. Mutagenesis by apurinic/aprimidinic sites. *Annu Rev Genet* 20: 201–230, 1986.
 88. Lucas JA, Masuda Y, Bennet RA, Strauss NS, and Strauss PR. Single-turnover analysis of mutant human apurinic/aprimidinic endonuclease. *Biochemistry* 38: 4958–4964, 1999.
 89. Luo M and Kelley MR. Inhibition of the human apurinic/aprimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. *Anticancer Res* 24: 2127–2134, 2004.
 90. Madhusudan S and Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. *Cancer Treat Rev* 31: 603–617, 2005.
 91. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg MJ, Dianov GL, and Hickson ID. Isolation of a small molecule inhibitor of DNA base excision repair. *Nucleic Acids Res* 33: 4711–4724, 2005.
 92. Madhusudhan S and Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. *Trends Mol Med* 11: 503–511, 2005.
 93. Martinvalet D, Zhu P, and Lieberman J. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. *Immunity* 22: 355–370, 2005.
 94. McNeill DR and Wilson DM 3rd. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. *Mol Cancer Res* 5: 61–70, 2007.
 95. Mendez F, Goldman JD, and Bases RE. Abasic sites in DNA of HeLa cells induced by lucanthone. *Cancer Invest* 20: 983–991, 2002.
 96. Mitomo K, Nakayama K, Fujimoto K, Sun X, Seki S, and Yamamoto K. Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-kappa B *in vitro*. *Gene* 145: 197–203, 1994.
 97. Mitra S, Izumi T, Boldogh I, Bhakat KK, Chattopadhyay R, and Szczesny B. Intracellular trafficking and regulation of mammalian AP-endonuclease 1 (APE1), an essential DNA repair protein. *DNA Repair (Amst)* 6: 461–469, 2007.
 98. Mol CD, Izumi T, Mitra S, and Tainer JA. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected]. *Nature* 403: 451–456, 2000.
 99. Mol CD, Hosfield DJ, and Tainer JA. Abasic site recognition by two apurinic/aprimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means. *Mutat Res* 460: 211–229, 2000.
 100. Nakamura J and Swenberg JA. Endogenous apurinic/aprimidinic sites in genomic DNA of mammalian tissues. *Cancer Res* 59: 2522–2526, 1999.
 101. Okazaki T, Chung U, Nishishita T, Ebisu S, Usuda S, Mishihiro S, Xanthoudakis S, Igarashi T, and Ogata E. A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium. *J Biol Chem* 269: 27855–27862, 1994.
 102. Ono Y, Furuta T, Ohmoto T, Akiyama K, and Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. *Mutat Res* 315: 55–63, 1994.
 103. Ozaki M, Suzuki S, and Irani K. Redox factor-1/APE suppresses oxidative stress by inhibiting the rac1 GTPase. *FASEB J* 16: 889–890, 2002.
 104. Parsons JL, Dianova II, and Dianov GL. APE1 is the major 3'-phosphoglycolate activity in human cell extracts. *Nucleic Acids Res* 32: 3531–3536, 2004.
 105. Peddi SR, Chattopadhyay R, Naidu CV, and Izumi T. The human apurinic/aprimidinic endonuclease-1 suppresses activation of poly(adp-ribose) polymerase-1 induced by DNA single strand breaks. *Toxicology* 224: 44–55, 2006.
 106. Pines A, Bivi N, Romanello M, Damante G, Kelley MR, Adamson ED, D'Andrea P, Quadrioglio F, Moro L, and Tell G. Cross-regulation between Egr-1 and APE/Ref-1 during early response to oxidative stress in the human os-

- teoblastic HOBIT cell line: evidence for an autoregulatory loop. *Free Radic Res* 39: 269–281, 2005.
107. Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M, Kelley MR, Quadrioglio F, and Tell G. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. *Nucleic Acids Res* 33: 4379–4394, 2005.
 108. Popoff SC, Spira AI, Johnson AW, and Demple B. Yeast structural gene (APN1) for the major apurinic endonuclease: homology to *Escherichia coli* endonuclease IV. *Proc Natl Acad Sci USA* 87: 4193–4197, 1990.
 109. Puglisi F, Aprile G, Minisini AM, Barbone F, Cataldi P, Tell G, Kelley MR, Damante G, Beltrami CA, and Di Loreto C. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. *Anticancer Res* 21: 4041–4049, 2001.
 110. Purohit S and Arenaz P. Molecular cloning, sequence and structure analysis of hamster apurinic/apyrimidinic endonuclease (chAPE1) gene. *Mutat Res* 435: 215–224, 1999.
 111. Rabik CA and Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat Rev* 33: 9–23, 2007.
 112. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, and Hillman GG. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy *in vitro* and *in vivo*. *Cancer Res* 67: 2141–2149, 2007.
 113. Rivkees SA and Kelley MR. Expression of a multifunctional DNA repair enzyme gene, apurinic/apyrimidinic endonuclease (APE; Ref-1) in the suprachiasmatic, supraoptic and paraventricular nuclei. *Brain Res* 666: 137–142, 1994.
 114. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH, and Kelley MR. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. *Cancer Res* 61: 2220–2225, 2001.
 115. Rosa S, Fortini P, Karran P, Bignami M, and Dogliotti E. Processing *in vitro* of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed *in vivo*. *Nucleic Acids Res* 19: 5569–5574, 1991.
 116. Roth RB and Samson LD. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. *Cancer Res* 62: 656–660, 2002.
 117. Sancar A and Sancar GB. DNA repair enzymes. *Annu Rev Biochem* 57: 29–67, 1988.
 118. Seiple LA, Cardellina JH, Akee R, and Stivers JT. Potent inhibition of human Ap endonuclease 1 by arylstibonic acids. *Mol Pharmacol* 73: 669–677, 2007.
 119. Seki S, Akiyama K, Watanabe S, Hatsushika M, Ikeda S, and Tsutsui K. cDNA and deduced amino acid sequences of a mouse DNA repair enzyme (APEX nuclease) with significant homology to *Escherichia coli* exonuclease III. *J Biol Chem* 266: 20797–20802, 1991.
 120. Sharma RA and Dianov GL. Targeting base excision repair to improve cancer therapies. *Mol Aspects Med* 28: 345–374, 2007.
 121. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, and Kolstoe DD. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. *Clin Cancer Res* 8: 3008–3018, 2002.
 122. Takao M, Kanno S, Kobayashi K, Zhang QM, Yonei S, van der Horst GT, and Yasui A. A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue. *J Biol Chem* 277: 42205–42213, 2002.
 123. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, and Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. *Mutat Res* 485: 269–281, 2001.
 124. Tell G, Damante G, Caldwell D, and Kelley MR. The intracellular localization of APE1/Ref-1: more than a passive phenomenon? *Antioxid Redox Signal* 7: 367–384, 2005.
 125. Tell G, Pellizzari L, Cimarosti D, Pucillo C, and Damante G. Ref-1 controls pax-8 DNA-binding activity. *Biochem Biophys Res Commun* 252: 178–183, 1998.
 126. Tell G, Zecca A, Pellizzari L, Spessotto P, Colombatti A, Kelley MR, Damante G, and Pucillo C. An 'environment to nucleus' signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. *Nucleic Acids Res* 28: 1099–1105, 2000.
 127. Tentori L and Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. *Pharmacol Res* 52: 25–33, 2005.
 128. Unk I, Haracska L, Johnson RE, Prakash S and Prakash L. Apurinic endonuclease activity of yeast Apn2 protein. *J Biol Chem* 275: 22427–22434, 2000.
 129. Walker LJ, Craig RB, Harris AL and Hickson ID. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. *Nucleic Acids Res* 22: 4884–4889, 1994.
 130. Wang D, Luo M, and Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. *Mol Cancer Ther* 3: 679–686, 2004.
 131. Wang H, Cheng E, Brooke S, Chang P, and Sapolsky R. Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. *J Neurochem* 87: 1527–1534, 2003.
 132. Wilson DM 3rd and Barsky D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. *Mutat Res* 485: 283–307, 2001.
 133. Wilson TM, Carney JP, and Kelley MR. Cloning of the multifunctional rat apurinic/apyrimidinic endonuclease (rAPEN)/redox factor from an immature T cell line. *Nucleic Acids Research* 22: 530–531, 1994.
 134. Wilson TM, Rivkees SA, Deutsch WA, and Kelley MR. Differential expression of the apurinic/apyrimidinic endonuclease (APE/ref-1) multifunctional DNA base excision repair gene during fetal development and in adult rat brain and testis. *Mutat Res* 362: 237–248, 1996.
 135. Xanthoudakis S and Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. *EMBO J* 11: 653–665, 1992.
 136. Xanthoudakis S, Miao G, Wang F, Pan YC, and Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. *EMBO J* 11: 3323–3335, 1992.
 137. Xanthoudakis S, Miao GG, and Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. *Proc Natl Acad Sci USA* 91: 23–27, 1994.
 138. Xanthoudakis S, Smeyne RJ, Wallace JD, and Curran T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. *Proc Natl Acad Sci USA* 93: 8919–8923, 1996.
 139. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, and Liu L. Combined treatment with temozolomide and

- methoxyamine: blocking apurinic/apyrimidinic site repair coupled with targeting topoisomerase II α . *Clin Cancer Res* 13: 1532–1539, 2007.
140. Yao K-S and O'Dwyer PJ. Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. *Biochem Pharmacol* 66: 15–23, 2003.
141. Yu SL, Lee SK, Johnson RE, Prakash L, and Prakash S. The stalling of transcription at abasic sites is highly mutagenic. *Mol Cell Biol* 23: 382–388, 2003.
142. Zhang JH, Chung TD, and Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 4: 67–73, 1999.
143. Zou GM, Luo MH, Reed A, Kelley MR, and Yoder MC. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. *Blood* 109: 1917–1922, 2007.
- Address reprint requests to:
Dr. Mark R. Kelley
Departments of Pediatrics
Herman B Wells Center for Pediatric Research
1044 W. Walnut, R4-302C
Indianapolis, IN 46202

E-mail: mkelley@iupui.edu
- Date of First submission to ARS Central, July 30, 2008; date of final revised submission, August 4, 2008; date of acceptance, August 20, 2008.